These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28628649)

  • 1. Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome.
    Zhao Z; Xie L; Bourne PE
    PLoS One; 2017; 12(6):e0179936. PubMed ID: 28628649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
    Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
    J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of carbazole derivatives as novel allosteric MEK inhibitors by pharmacophore modeling and virtual screening.
    Xi D; Niu Y; Li H; Noha SM; Temml V; Schuster D; Wang C; Xu F; Xu P
    Eur J Med Chem; 2019 Sep; 178():802-817. PubMed ID: 31252285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
    Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
    Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration and Comparison of the Geometrical and Physicochemical Properties of an αC Allosteric Pocket in the Structural Kinome.
    Sturm N; Tinivella A; Rastelli G
    J Chem Inf Model; 2018 May; 58(5):1094-1103. PubMed ID: 29697977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gaining Insights into Key Structural Hotspots within the Allosteric Binding Pockets of Protein Kinases.
    Bhujbal SP; Jun J; Park H; Moon J; Min K; Hah JM
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What Makes a Kinase Promiscuous for Inhibitors?
    Hanson SM; Georghiou G; Thakur MK; Miller WT; Rest JS; Chodera JD; Seeliger MA
    Cell Chem Biol; 2019 Mar; 26(3):390-399.e5. PubMed ID: 30612951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors.
    Panicker RC; Chattopadhaya S; Coyne AG; Srinivasan R
    Adv Exp Med Biol; 2019; 1163():253-278. PubMed ID: 31707707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Biological Evaluation of CK2 Allosteric Fragments through Structure-Based Virtual Screening.
    Li C; Zhang X; Zhang N; Zhou Y; Sun G; Zhao L; Zhong R
    Molecules; 2020 Jan; 25(1):. PubMed ID: 31935979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QM/MM and molecular dynamics investigation of the mechanism of covalent inhibition of TAK1 kinase.
    Toviwek B; Gleeson D; Gleeson MP
    Org Biomol Chem; 2021 Feb; 19(6):1412-1425. PubMed ID: 33501482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing an allosteric inhibitor-induced inactive state in with-no-lysine kinase 1 using Gaussian accelerated molecular dynamics simulations.
    Jonniya NA; Sk MF; Kar P
    Phys Chem Chem Phys; 2021 Mar; 23(12):7343-7358. PubMed ID: 33876094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.
    Deibler KK; Mishra RK; Clutter MR; Antanasijevic A; Bergan R; Caffrey M; Scheidt KA
    ACS Chem Biol; 2017 May; 12(5):1245-1256. PubMed ID: 28263556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors.
    Bagal SK; Omoto K; Blakemore DC; Bungay PJ; Bilsland JG; Clarke PJ; Corbett MS; Cronin CN; Cui JJ; Dias R; Flanagan NJ; Greasley SE; Grimley R; Johnson E; Fengas D; Kitching L; Kraus ML; McAlpine I; Nagata A; Waldron GJ; Warmus JS
    J Med Chem; 2019 Jan; 62(1):247-265. PubMed ID: 29672039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases.
    Cowan-Jacob SW; Jahnke W; Knapp S
    Future Med Chem; 2014 Apr; 6(5):541-61. PubMed ID: 24649957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
    Badrinarayan P; Sastry GN
    J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and SAR of a new series of thieno[3,2-d]pyrimidines as Tpl2 kinase inhibitors.
    Ni Y; Gopalsamy A; Cole D; Hu Y; Denny R; Ipek M; Liu J; Lee J; Hall JP; Luong M; Telliez JB; Lin LL
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5952-6. PubMed ID: 21862328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bitopic Inhibition of ATP and Substrate Binding in Ser/Thr Kinases through a Conserved Allosteric Mechanism.
    Ma N; Lippert LG; Devamani T; Levy B; Lee S; Sandhu M; Vaidehi N; Sivaramakrishnan S
    Biochemistry; 2018 Nov; 57(45):6387-6390. PubMed ID: 30339352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics simulation and QM/MM calculation reveal the selectivity mechanism of type I 1/2 kinase inhibitors: the effect of intramolecular H-bonds and conformational restriction for improved selectivity.
    Wang H; Gao Z; Song P; Hu B; Wang J; Cheng M
    Phys Chem Chem Phys; 2019 Nov; 21(43):24147-24164. PubMed ID: 31657381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation.
    Verkhivker GM
    Mol Biosyst; 2016 Oct; 12(10):3146-65. PubMed ID: 27481329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Promise and Opportunities for Allosteric Kinase Inhibitors.
    Lu X; Smaill JB; Ding K
    Angew Chem Int Ed Engl; 2020 Aug; 59(33):13764-13776. PubMed ID: 31889388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.